Skip to main content

memo - Magazine of European Medical Oncology OnlineFirst articles

15.08.2019 | short review Open Access

Systemic treatment of metastatic breast cancer: SABCS 2018

This review summarizes clinically relevant trials in metastatic breast cancer (MBC) presented at the 2018 San Antonio Breast Cancer Symposium (SABCS). At the meeting updates of two large phase III studies were presented: (1) the biomarker analysis …

Theresa Westphal, Simon Peter Gampenrieder, MD Richard Greil

15.08.2019 | short review

HIV-triggered lymphoma

Treatment outcomes of AIDS-related lymphomas (acquired immune deficiency syndrome, ARL) have improved, nearing those reported for HIV-negative (human immunodeficiency virus) cohorts; recommended treatment protocols are herewith presented. The …

Dr. Bernd Lorenz Hartmann, Michèle Desiré Atzl

12.08.2019 | short review Open Access

ASH 2018—Highlights in Multiple Myeloma

More than 900 abstracts on multiple myeloma were presented at this year’s ASH in San Diego. Several trials explored the addition of the monoclonal antibody daratumumab to established treatment regimens in both newly diagnosed as well as relapsed …

MD Dr. Georg Jeryczynski, MD Assoc. Prof. PD Dr. Maria-Theresa Krauth

07.08.2019 | case report Open Access

A wearable cardioverter defibrillator for prevention of sudden cardiac death in a hematologic patient—a case report

The wearable cardioverter defibrillator (WCD) is a suitable option to overcome life-threatening episodes of malignant arrhythmia. There is much experience in the use of these devices in patients with idiopathic arrhythmia as well as in patients at …

Stefan Hatzl, Hildegard T. Greinix, Philipp Kreuzer, Eduard Schulz, Peter Neumeister, Daniel Scherr

02.08.2019 | short review

Cure is not enough! Why it is time to act and close the gap

Survivors speaking up

Many publications on optimization of treatments in paediatric oncology are introduced by the good news that in Europe survival rates of paediatric cancers have increased enormously over the past decades, from 20% up to over 80%, depending on …

Carina Schneider, Jaap den Hartogh, Katharina Feckter, Zuzana Tomášiková, Anita Kienesberger, CCI Europe Survivors Network, CCI Europe

30.07.2019 | short review

ASH 2018 — aggressive lymphoma

At the American Society of Hematology Meeting (ASH) 2018 promising data were presented reflecting the impressing advances of clinical research in aggressive lymphoma. 

Dr. Michael Panny

25.07.2019 | short review

Cutaneous melanoma—The benefit of screening and preventive measures

The incidence rates of cutaneous melanoma are continually rising in the Caucasian population with the highest rates in Australia and New Zealand. The genesis of melanoma is a complex interplay between genetic predisposition and exogenous factors.

MD Magdalena Seidl-Philipp, MD Van Anh Nguyen

25.07.2019 | Onkologie und Hämatologie | short review Open Access

Post San Antonio Breast Cancer Symposium 2018

Local and operative therapy, radiotherapy

This short review summarizes the most important facts presented at the San Antonio Breast Cancer Symposium 2018 concerning local therapy of breast cancer, including breast and lymph node surgery as well as radiotherapy. 

F.E.B.S. PD Dr. Ruth Exner

17.07.2019 | short review

Checkpoint inhibitors in head and neck cancer

Head and neck cancer (HNC) are aggressive cancers and represents the sixth leading cancer by incidence worldwide. This kind of cancer constitutes about 3% of all newly diagnosed malignant tumors in humans, and this percentage is likely to increase …

Dr. Ilson Sepulveda, Rodrigo Ascui, A. Andrés Capizzano

16.07.2019 | short review

Post San Antonio: immunotherapy, chemotherapy and new combinations

This article gives a summary of several studies presented at the San Antonio Breast Cancer Symposium in 2018. In specific, the biomarker analysis of the ‘IMpassion130’ trial, the effects of CDK4/6 inhibitors on T-cells and tumor immunogenicity …

MD Karl Mayrhofer, MD, MBA Kathrin Strasser-Weippl

12.07.2019 | short review Open Access

Risk of cancer after long-term therapy of autoimmune disorders with glucocorticoids or DMARDs—a controversial issue

Most autoimmune diseases like RA (rheumatoid arthritis) are usually associated with lifelong treatment. The etiology of RA remains unclear, but it depends on a high-risk genetic background and an environmental trigger, which leads to autoimmune …

OA Dr. Jakob D. Rudzki

10.07.2019 | review Open Access

Immunosuppression after renal transplantation

Immunosuppression (IS) is administered to kidney transplant recipients to prevent rejection episodes and loss of the renal allograft. Most centers rely on a triple IS after induction with either interleukin‑2 receptor antibodies or antithymocyte …

Hannes Neuwirt, Michael Rudnicki, Peter Schratzberger, Markus Pirklbauer, Andreas Kronbichler, Gert Mayer

01.07.2019 | short review

Skin tumours in organ transplant recipients—implications for the plastic surgeon

Squamous cell carcinoma of the skin (SCC) and basal cell carcinoma (BCC) are common entities, often with a benign course. Tumour biology, however, is different in immunosuppressed individuals, such as organ transplant recipients (OTR). As …

M.D. Johanna Krapf, M.D. Gerhard Pierer

26.06.2019 | case report

Giant leiomyoma of the renal capsule: CT and MR imaging features with pathologic correlations

Renal leiomyoma (RL) is a rare benign tumor, usually presenting as a small asymptomatic lesion, frequently found during autopsy with a higher incidence in women (2:1). However, larger RL can become symptomatic and show structural changes (such as …

Arnaldo Stanzione, Michele Santangelo, Filippo De Rosa, Andrea Ponsiglione, Gaia Peluso, Luigi Insabato, MD Massimo Imbriaco

12.06.2019 | case report Open Access

Immunotherapeutic approach to a case of advanced hepatoid adenocarcinoma of the lung

Hepatoid adenocarcinomas (HAC), first described in 1985 by Ishikura et al. [ 1 ], are a rare type of extrahepatic alpha-fetoprotein secreting tumor with hepatocellular carcinoma (HCC) like morphology. Since that time, only 33 cases of HAC of the …

Anthony El Khoury, Marc El Khoury, Russel De Luca

12.06.2019 | case report

Head and neck Langerhans cell histiocytosis: two case reports and review of the literature

Langerhans cell histiocytosis (LCH) is an inflammatory neoplasia of myeloid precursor cells driven by mutations in the mitogen-activated protein kinase (MAPK) pathway. It can present as single or multisystem LCH. It occurs in 0.5–5.4 per million …

Dr. Ilson Sepúlveda, Ignacio Mendoza, Romina Novoa, Geraldine Ayres, Nadia Inostroza, J Patricio Ulloa, Francisco Rivas-Rodriguez

17.05.2019 | short review Open Access

Update in thrombosis and hemostasis: ASH meeting 2018

In the field of thrombosis and hemostasis the focus was laid on the prophylaxis and treatment of venous thromboembolism in patients with active cancer during this years’ meeting of the American Society of Hematology (ASH) in San Diego. The …

MD Clemens Feistritzer